InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Black Diamond Therapeutics, Inc.

BDTX Clue Score71
United States Fiscal year ends December CIK 0001701541
$1.83 +1.10% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.83 −76.48% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 30 Jan 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2018Revenue0.0Operating income−8.9Net income−8.9Fiscal year 2019Revenue0.0Operating income−29.3Net income−35.3Fiscal year 2020Revenue0.0Operating income−69.6Net income−67.3EPS, diluted−2.05Fiscal year 2021Operating income−126.9Net income−125.6EPS, diluted−3.47Fiscal year 2022Operating income−92.8Net income−91.2EPS, diluted−2.52Fiscal year 2023Operating income−86.5Net income−82.4EPS, diluted−1.88Fiscal year 2024Revenue0.0Operating income−78.8Net income−69.7EPS, diluted−1.27Fiscal year 2025Revenue70.0Operating income12.5Net income22.4EPS, diluted0.39
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 0.0 n/a n/a n/a 0.0 70.0
Growth
Operating income −8.9 −29.3 −69.6 −126.9 −92.8 −86.5 −78.8 12.5
Net income −8.9 −35.3 −67.3 −125.6 −91.2 −82.4 −69.7 22.4
Growth
EPS, diluted n/a n/a −2.05 −3.47 −2.52 −1.88 −1.27 0.39
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025Operating margin17.9%Net margin32.0%
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a 17.9%
Net margin n/a n/a n/a n/a n/a n/a n/a 32.0%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−8.5Capital expenditure−0.1Free cash flow−8.5Fiscal year 2019Operating cash flow−24.7Capital expenditure−0.0Free cash flow−24.7Fiscal year 2020Operating cash flow−52.1Capital expenditure−0.1Free cash flow−52.3Fiscal year 2021Operating cash flow−100.1Capital expenditure−2.7Free cash flow−102.9Fiscal year 2022Operating cash flow−85.1Capital expenditure−0.2Free cash flow−85.3Fiscal year 2023Operating cash flow−66.7Capital expenditure−0.0Free cash flow−66.8Fiscal year 2024Operating cash flow−62.3Capital expenditure0.0Free cash flow−62.3Fiscal year 2025Operating cash flow29.6
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −8.5 −24.7 −52.1 −100.1 −85.1 −66.7 −62.3 29.6
Capital expenditure −0.1 −0.0 −0.1 −2.7 −0.2 −0.0 0.0 n/a
Free cash flow −8.5 −24.7 −52.3 −102.9 −85.3 −66.8 −62.3 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2018Cash51.7Shareholders’ equity−15.5Fiscal year 2019Cash154.7Shareholders’ equity−47.2Fiscal year 2020Cash34.6Shareholders’ equity307.8Fiscal year 2021Cash65.8Shareholders’ equity195.9Fiscal year 2022Cash34.3Shareholders’ equity115.7Fiscal year 2023Cash56.2Shareholders’ equity116.7Fiscal year 2024Cash36.4Shareholders’ equity83.3Fiscal year 2025Cash21.0Shareholders’ equity112.2
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 51.7 154.7 34.6 65.8 34.3 56.2 36.4 21.0
Shareholders’ equity −15.5 −47.2 307.8 195.9 115.7 116.7 83.3 112.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.0 0.0 0.0 n/a n/a n/a 0.0 70.0
Growth
7.0 21.8 48.2 96.8 64.4 59.4 51.3 33.6
2.0 7.6 21.4 30.0 28.4 27.1 27.5 16.6
−8.9 −29.3 −69.6 −126.9 −92.8 −86.5 −78.8 12.5
Growth
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−8.9 −35.3 −67.3 −125.6 −91.2 −82.4 −69.7 22.4
Growth
Per share
n/a n/a −2.05 −3.47 −2.52 −1.88 −1.27 0.39
n/a n/a −2.05 −3.47 −2.52 −1.88 −1.27 0.39
Growth
n/a n/a 32.9 36.2 36.3 44.0 55.0 56.9
n/a n/a 32.9 36.2 36.3 44.0 55.0 57.6
Growth +10.0% +0.4% +21.0% +25.2% +4.6%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 74.9% in five years, which is dilution.
  • A net loss in 7 of 8 years on file.